Despite decades of progress in cancer immunotherapy, glioblastoma remains largely resistant due to blood-brain barrier constraints, tumor heterogeneity, and an immunosuppressive microenvironment; advances in recombinant antibody engineering—including multispecific formats, nanobody fusions, and Fc optimization—are emerging as potential strategies to address these long-standing biological and translational barriers.
